The prevalence of diabetes is less in China compared to other developed and developing nations, but as it houses the largest population in the world, it provides plethora of opportunities to the pharmaceutical players entering in this market. Besides, amid increasing concerns towards health and increasing awareness about chronic diseases, like diabetes among the consumers, the diabetic drug market is expected to show decent growth in the coming years. Consequently, the oral diabetic drug market in the country is anticipated to grow at a CAGR of around 5.3% during 2012 - 2014, says our new research report “China Diabetes Market Analysis”.
Moreover, our team of experts has done an extensive research on the Chinese diabetes market and found that, the sales uptake is not only driven by the soaring patient numbers, but also by the launch of many novel anti diabetic products viz. dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. Moreover, another factor, which will help in the growth of the sector, is the china’s dissemination of health care insurance throughout the country, which has increased the sales of drugs across the country.
Our report has segmented the diabetes market into diabetes drug market, insulin delivery devices market, and glucose monitoring devices market. For all the segments, proper concentration has been given to all the sub segments. Further, detail statistics and description regarding trends prevailing in the segments has been covered in the report.
“China Diabetes Market Analysis” provides thorough research and rational analysis along with reliable statistics of the Chinese diabetic industry. The report also provides extensive information on the traditional markets as well as on the emerging technologies. Besides, an insight of trends prevailing in the Chinese diabetes market has been covered in the report. Analysis and statistics regarding market size, growth, share, and segmentation have been thoroughly studied in the report to present a comprehensive view of the Chinese diabetes market.
For more information visit: http://www.rncos.com/Report/IM347.htm |
